{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038873","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.362715+00:00","generated_at":"2026-05-17T18:39:07.497308+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance","bullets":["Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.","Non-GAAP net income $10.7M ($0.24 EPS) vs $2.9M ($0.07) YoY; adjusted EBITDA $24.8M (+33%).","On-X +24%, stent grafts +24%, BioGlue +4%, Preservation +3% constant currency growth.","FY 2025 guidance raised: constant currency growth now 12-14%; reported revenue $435-443M.","Retired $99.5M of convertible notes; FDA IDE approved for Arcevo LSA pivotal trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038873","json":"https://secwatch.observer/filing/0001628280-25-038873.json","markdown":"https://secwatch.observer/filing/0001628280-25-038873.md","text":"https://secwatch.observer/filing/0001628280-25-038873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000162828025038873/0001628280-25-038873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000162828025038873/aort-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:39:07.497308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}